FDA: Multaq Not Safe for Use in Subgroup of AF Patients

The FDA is requiring a boxed warning for Sanofi-Aventis’ atrial fibrillation (AF) treatment Multaq in patients with permanent AF after a safety review showed a higher risk of cardiovascular (CV) death.
Washington Drug Letter